Kaiser Permanente Ventures

We focus on investment opportunities within the healthcare and life science markets where we can identify value early. At the core of our investment philosophy is a committed and collaborative approach to working with management teams and syndicate partners to build successful companies. We work actively with founders, providing guidance, support and access to our network. We strongly believe that no two investments are the same and support the most suitable business model for each individual venture, working with management teams to formulate strategies to achieve financial independence. We are comfortable financing companies by ourselves and, if appropriate, working closely with the founders to help build a syndicate of co-investors who bring complementary relationships and share our vision. We have a 14-year history of continuous dedication to the fast growing MedTech sector and a history of backing successful entrepreneurs transforming healthcare through MedTech innovation. Investment Strategy Focus: Within the broader healthcare market, we focus our investments on medical technologies including medical devices, diagnostics, drug delivery, and digital health. We back both first-time and experienced founders, who value our participation as well our capital. Stage: We are typically the first institutional investor and support companies through early product and clinical development and often through the regulatory process. We make our first investment at the seed through series B stage, based on when the risk of translation from pre-clinical to clinical is at its lowest. We are life cycle investors and continue to support our portfolio companies through to exit. Capital Efficiency: We invest in companies that are able to demonstrate early and meaningful clinical value with minimum capital invested and preserve the most appropriate exit opportunity. Therapeutic Indications: While we are agnostic to therapeutic indication, we invest in companies developing products that address large, global markets and where there is significant unmet clinical need. We particularly like therapeutic devices that significantly improve patient outcomes and diagnostics that fundamentally change the course of therapeutic intervention.

Intuitive Ventures invests in and accelerates the digital, therapeutic, diagnostic, and device ecosystems of minimally invasive care. Our unique access to Intuitive’s industry-leading knowledge, care delivery innovation, and commercial reach, empowers us to cultivate the potential of startups that are advancing positive outcomes in healthcare. Through our inaugural $100 million fund, Intuitive Ventures is focused on accelerating the future of minimally invasive care by moving the ecosystem forward. What we do Intuitive Ventures extends Intuitive's commitment to converging robotic systems, digital tools, and clinical need in search of new ways to understand, diagnose, treat, and manage disease. We apply Intuitive’s strengths and abilities in the fields of robotic surgery and minimally invasive care to support independent initiatives in four focus areas: Digital – transformative business models and solutions improving outcomes across the patient care continuum Therapeutics – precision focal therapeutics and biotech innovations delivered to the right patient at the right place and the right time Diagnostics – powering earlier disease detection and therapeutic activation across clinical pathways Devices – novel and digitally-native medical device platforms pushing the boundaries of patient care What sets us apart: Aligned for success – our nimble structure and financial alignment empower us to invest early and to support our portfolio companies pioneer markets Wealth of experience – we provide the resources and guidance needed to support our entrepreneurs and management teams reach their major milestones Deep strategic value – we leverage the unique strengths of Intuitive to accelerate the impact of our portfolio companies

Pureland Global Venture is a direct investment fund and part of the Pureland Group which targets impact investment deals in the medical technology sector. We are Singapore-based with a focus in APAC, India and the US. The fund deals with early-stage companies who have potential to inject value into the patient care system, save lives and reduce gaps in the supply and demand chains. Since we were established, we have invested in multiple medical sectors in both medical devices and ML-based solutions. MISSION - WHAT WE WANT TO ACHIEVE Established with the goal of giving people access to healthcare and also providing them with clinical choices, our mission is to bring medical solutions and savings to 100 million people around the world. We strongly believe in people who don’t just care about profit and who want to make the world a better place by solving real issues and pushing forward the latest evolution in medical technology. We envision bringing together impactful start-ups, commercial partners, insightful advisors and clinical providers in order to build a sustainable foundation for affordable, accessible and high-quality healthcare. WHY HEALTHCARE? Worldwide healthcare spending is expected to continue to rise at an alarming rate with a slight difference in some countries. Of all the leading factors, life expectancy appears to still be on the rise. By 2050, 1/6 people in the world will be over the age of 65 (16%), an increase from 1/11 in 2019 (9%). The number of people aged over 80 is projected to be 426 million by 2050 according to the United Nations population prospects. As we are entering a smart-health generation, the ecosystem demands more cost-effective solutions and appropriate treatments which can be delivered at the appropriate time and location. Clinicians use technology to give more holistic solutions to an aging population and provide more accurate diagnostics. Care delivery stakeholders use data and communicate more effectively and efficiently. Patients are involved in their own treatment plans and more healthcare access is delivered to people who did not previously have access. Unfortunately, we still face issues such as the increasing cost of healthcare, aging population, limited resources and shortages of healthcare professionals in various parts of the world. In order to combat these problems, government support and spending alone is not enough. We believe that these shortages can be filled by technology, which can be our solution for ensuring sufficient healthcare for future generations. This is also the reason why we are keen on enterprises which can provide solutions to combat these issues and create positive changes in the smart-health era. Founded in Singapore, we hope to be able to leverage the geographical advantage of Asia, and put together growth opportunities for these technologies which will make them accessible globally in the long term. WE SUPPORT START-UPS POST INVESTMENTFOUNDER SUPPORT: Start-ups regularly face critical decision-making as businesses grow from continuous market feedback and unexpected situations. We understand how difficult it can be and we will work together with the founders as a team in order to assist them with scaling their company, whether from networking referrals at the R&D stage, business strategy improvement at the growth stage, or EBITDA optimisation at a later stage. We offer support to founders for the optimisation of team structure as their businesses grow so they can overcome challenges and compete globally. MANUFACTURING SUPPORT: Manufacturing is one of the most crucial aspects of any device company, but it is often where mistakes are made. We advise our companies who experience manufacturing challenges from prototyping to mass production. In order to achieve this, we provide strategic value to our portfolio companies by connecting them to cost-effective manufacturing partners throughout the plastic, PCBA, silicon/rubber and final assembly industries. Our partners are high-mix and low-volume suppliers who understand the challenges of start-ups. Outside of production, we assist companies with lower case costing, set-up and management. GOVERNANCE: Establishing a good corporate culture and necessary internal control will mitigate business losses from major risks and lay the foundations for a company to improve. In a later stage funding cycle, correct corporate governance and internal control are paramount before larger funds buy into the company’s vision and growth story. We have a complete understanding of control and our networks are comprised of global experts in financial knowledge and risk assurance who can work together with our companies. FUNDRAISING: We typically fund companies while they are still young, from their seed to their series A round. Given the heavy research and development nature of medical technology companies, they usually require additional funding in order to boost their business quickly. Post-investment, we will not only collaborate on budgets and milestone adjustments but will more importantly offer assistance with financial modeling and revenue projection. This ensures that companies gain a higher chance of future investment. Finally, we work with other larger funds all over the world who specialise in revenue growth in order to understand their needs when they select their investment targets. EXIT: We seek founders with longer-term goals and a desire to take their companies to global players. Given our evergreen nature and flexible exit strategy, we are well suited to the long operation cycle of healthcare companies. At the same time, we understand and respect that some founders have a shorter term goal of M&A to boost market shares, expand business services or leverage bigger players to scale the company. We are experienced in company buy-out considerations and offer our support to founders as long as the company fits within our investment mandate.

DaVita Venture Group is committed to building partnerships with health care innovators to help improve the lives of patients with kidney disease and related conditions. Together, we believe we can transform the future of patient care for the better. Our Strategy We aim to invest in, acquire, and co-develop products, solutions and businesses that improve care for patients with kidney disease and related conditions. PrioritiesCare Delivery Models: Advancements to expand access to care and improve clinical outcomes through adoption of tech-enabled services, home treatments and value-based care Life Sciences: Pharmaceuticals, medical devices and diagnostics that can improve clinical outcomes and patient experience while reducing costs Digital Health: Products and services that leverage technology, data and connectivity to improve care delivery

Our unique model combines first access and proprietary rights to disruptive deal flow with an established track record of new venture formation, company building, and value creation. We invest in bold, transformative innovations to develop new drugs and technologies to improve outcomes for the market benefit of patients worldwide. Investing in early-stage venture capital We invest in seed and early-stage life science ventures, bringing Mass General Brigham’s expertise and extensive network to bear to create transformative solutions to solve unmet medical needs. Leveraging a competitive advantage Research is the driving force that advances medicine and Mass General Brigham Ventures sits at the center of the largest medical research engine in the United States. #1 in hospital medical research​ Mass General Brigham Ventures is a member of the largest hospital system-based research enterprise in the U.S., which includes Massachusetts General Hospital and Brigham and Women’s Hospital, two of the nation’s premier academic medical centers whose origins date back to the early 1800’s.​ Mass General Brigham Ventures' unique model leverages a preferred position to source technology including first access and rights to disruptive deal flow. This is an exceptional advantage that conventional venture capital funds cannot reproduce. Legacy of investing in medical innovation Mass General Brigham Ventures plays a key role in founding and funding next-generation technologies. These three transformational companies are examples of start-ups that are poised to address significant unmet medical needs. All were seeded by Mass General Brigham Ventures with founding intellectual property from Mass General Brigham. Editas Medicine: IPO Feb. 2016 (NASDAQ: EDIT) Unlocking the power and potential of CRISPR genome editing technology. CoStim Pharmaceuticals: Acquired by Novartis, Feb. 2014 Next-generation immuno-oncology drugs based on T-cell costimulatory targets. Keros Therapeutics: IPO April 2020 (NASDAQ: KROS) Novel treatments for patients suffering from hematologic and musculoskeletal disorders. Our investment strategy We invest in next-generation life science companies based on intellectual property created within our own research community. We seek strong co-investor syndicates to develop products across a range of categories including drugs, devices, diagnostics, and digital health.​ Initial investments are directed at the seed and Series A stages, where our participation attracts capital and talent into the most difficult-to-fund phase of company development. When we invest, we expect to support each portfolio company through its entire financing lifecycle. In addition to providing the necessary venture capital, we leverage our experience in starting and growing companies, our expertise in the medical industry, and our network of scientific and business talent to build great companies. Leveraging a proven approach:The annual output of high-impact invention and discovery represents a unique opportunity to create, finance, and monetize new life science-based companies. We deploy start-up capital to capture the collective expertise of our unrivaled base of scientific talent and clinical resources to bring cutting-edge science to patients Competitive advantage of Mass General Brigham: The power of collective impact from our vast research enterprise provides an unrivaled competitive advantage to build next generation life science companies capable of bringing innovative therapeutics to patients in need and delivering outstanding returns to our investors. Academic medical centers: We source deals from our five research and teaching hospitals, which collectively represent the largest teaching affiliate of Harvard Medical School.

Qiming Venture Partners is a top-tier VC firm with outstanding reputation. With our exceptional investment performances, we have been widely recognized by investors from around the world. We have a reputation for being entrepreneur friendly. Why Choose Us Founded in 2006, Qiming Venture Partners is a leading global venture capital firm. Currently, Qiming Venture Partners manages eleven US Dollar funds and seven RMB funds with $9.5 billion in capital raised. Since our establishment, we have invested in outstanding companies in the Technology and Consumer (T&C) and Healthcare industries at the early and growth stages. Since our establishment, Qiming Venture Partners has earned extensive recognition from investors worldwide and has become an ideal VC firm for entrepreneurs, due to our exceptional investment performance. Qiming Venture Partners and our partners consistently rank among the leaders in the global venture capital industry across various prestigious lists. Experienced Investment Team Our professional investment team consists of founders, entrepreneurs, scientists, engineers, doctors, consultants, and financial experts. We have extensive experiences in building and operating a business. We are happy to share our experiences and resources with entrepreneurs. Exceptional Investment Performances Qiming strives to be the preferred investor for top entrepreneurs. For the past decades, we seized the opportunity of changing world with technologies. We have invested in companies that later become industry unicorns and listed companies, which delivered excellent returns for our LP investors. Since our debut, we have backed over 530 fast-growing and innovative companies. Over 200 of our portfolio companies have achieved exits through IPOs at the NYSE, NASDAQ, HKEX, Shanghai Stock Exchange, or Shenzhen Stock Exchange, or through M&A or other means. There are also over 70 portfolio companies that have achieved unicorn or super unicorn status. Many of our portfolio companies are today’s most influential firms in their respective sectors, including Xiaomi (SEHK:1810), Meituan (SEHK:3690), Bilibili (NASDAQ:BILI, SEHK:9626), Zhihu (NYSE:ZH, SEHK:2390), Roborock (SHSE:688169), Gan & Lee Pharmaceuticals (SHSE:603087), Tigermed (SZSE:300347, SEHK:3347), Zai Lab (NASDAQ:ZLAB, SEHK:9688), CanSino Biologics (SEHK:6185, SHSE:688185), Schrödinger (NASDAQ:SDGR), APT Medical (SHSE:688617), New Horizon Health (SEHK:6606), Sanyou Medical (SHSE:688085), AmoyDx (SZSE:300685), Berry Genomics (SZSE:000710), SinocellTech (SHSE:688520), UBTech (SEHK:9880), Yuanxin Technology, Caidya, Belief BioMed, WeRide, among many others. Adequate Resources and Experiences to Help Grow a Start-up to an Enterprise We always fully respect entrepreneurs. We are entrepreneurs' companions along their way of achieving dreams and building great companies. We leverage our industry resources to provide a broad range of support to entrepreneurs. We have built a unique Qiming ecosystem that can provide value-added services to portfolio companies, which creates beautiful chemistries between our portfolio companies. More and more new investments are made from the upstream or downstream of our portfolio companies, or from the recommendations of the portfolio companies. Increasing more of our portfolio companies started to cooperate intensively with each other. We help entrepreneurs make strategically critical decisions. When entrepreneurs are at a crossroads, we do our best to help them choose the right direction. We share industry insights with entrepreneurs so that they can better navigate the business world. We share our industry resources to entrepreneurs. Our extensive network in both East and West enables entrepreneurs with diversified resources, which helps them optimize their business model and become an industry leader. We help portfolio companies build strong teams and provide them with consulting support. We help entrepreneurs improve the leadership capacities and find their core team members to become long-term partners. We can connect entrepreneurs with management, finance, legal, and marketing professionals. We value important milestones such as financing, IPOs and M&As. We respect entrepreneurs with their own choices regarding the timing, location and approaches of financial activities. We work hand-in-hand with entrepreneurs, help them select the appropriate intermediaries, and sort out the strategic positioning, market scale, business structure and growth potential for the companies. Investment Strategies We are committed to finding great companies for the future and bring long-term value to societies. Our investment team spends a lot of time researching industry trends, technology developments, and changes in consumer habits. Through these studies, we hope to capture a huge future market as early as possible. At the same time, we also attach great importance to in-depth and detailed due diligence. We make comprehensive contact with entrepreneurs, through a deep understanding of the business operations and scientific research data, we can better grasp investment opportunities and assess investment risks. Another essential component of our investment strategy is “focus”. We hope to have good insights and rich contacts for the industries we care about, truly understand the projects we invested in, be able to help after the investment, and form an ecosystem within our portfolio companies, to help start-ups grow from multiple perspectives. What Do We Invest Since our inception in 2006, we have been in touch with tens of thousands of founding teams of startup companies. On average, one out of 30 companies receives our funding. Seventy percent of our investments are in Series-A, and many of our portfolio companies will become industry leaders in less than seven years. T&C: We invest in information technology and new consumer business patterns. We focus on mobile internet, social networking, and entertainment. We value how technology redefines business, education, and transport. We pay close attention to new core technologies, including artificial intelligence, robotics, semiconductors, enterprise software, blockchain and so forth. We have great interests in manufacturing upgrade opportunities. Healthcare: We have invested in over one hundred start-ups in the healthcare sector. Our healthcare investments are majorly in diagnostics, R&D, equipment, and services fields. In recent years, we started to pay close attention to AI-related "Digital Healthcare" sector. What we can bring to entrepreneurs?We are committed to finding great companies for the future to bring long-term value to people and society We share our industry resources with entrepreneurs We have a complete trust relationship with stakeholders, especially with our investors and entrepreneurs We help entrepreneurs build strong teams and provide them with consulting supports We build a unique ecosystem to provide value-added services to entrepreneurs We value important milestones including financing, IPOs and M&As We provide support to entrepreneurs when they make strategically critical decisions